Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide

AAPS PharmSciTech

Volumn 16, Issue 3, 2015, Pages 554-568

  Banerjee, Arti ^a   Verma, P R P ^b   Gore, Subhash ^a  

^a Research and Development Center   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

convolution approach; gliclazide; hot melt extrusion (HME); hydroxypropyl cellulose; solid dispersion

Indexed keywords

GLICLAZIDE; HYDROXYPROPYLCELLULOSE; CELLULOSE; DELAYED RELEASE FORMULATION; EXCIPIENT; TABLET;

ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED POROSITY OSMOTIC PUMP TABLET; CONTROLLED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MINIMUM PLASMA CONCENTRATION; OSMOTIC PRESSURE; PH; PRIORITY JOURNAL; ROTATION; SOLID STATE; STEADY STATE; TABLET; TABLET COMPRESSION; TABLET FORMULATION; TABLET POROSITY; THERMAL ANALYSIS; WEIGHT GAIN; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; KINETICS; MEDICINAL CHEMISTRY; OSMOSIS; POROSITY; PROCEDURES; SOLUBILITY;

BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GLICLAZIDE; KINETICS; OSMOSIS; OSMOTIC PRESSURE; POROSITY; SOLUBILITY; TABLETS;

EID: 84929965115     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0246-0     Document Type: Article

References (58)

1. International Diabetes Federation. IDF diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation; 2013. Available from http://www.idf.org/diabetesatlas. Last accessed 24 April 2014.
2. Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams textbook of endocrinology. 12th ed. Philadelphia: Elsevier/Saunders; 2012. p. 1371–435.
3. Philip E, Cryer MD. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.
4. Narayan KM, Thompson TJ, Boyle JP, Beckles GL, Engelgau MM, Vinicor F, et al. The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males. Health Care Manag Sci. 1999;2:223–7.
5. Leif C, Groop MD. Sulfonylureas in NIDDM. Diabetes Care. 1992;15(6):737–54.
6. Grbic S, Parojcic J, Ibric S, Duric Z. In vitro–in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. AAPS PharmSciTech. 2011;12(1):165–71.
7. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in noninsulin‐dependent diabetes mellitus. Drugs. 1993;46(1):92–125.
8. Dollery C. Therapeutic Drugs. 2nd ed. London:Churchill Livingstone; 1991.
9. Harrower AD. Comparison of efficacy, secondary failure rate and complications of sulfonylurea. J Diabetes Complicat. 1994;8:201–3.
10. Chazan ACS, Gomes MB. Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure. Braz J Med Biol Res. 2001;34(1):49–56.
11. Devireddy SR, Veerareddy PR. Solubility and bioavailability improvement of glcclazide by solid dispersions using novel carriers. Int J Drug Deliv. 2012;4:455–61.
12. Mohammad‐Reza R, Afshin M, Mohammad‐Hosein T. A simple and sensitive HPLC method for determination of gliclazide in human serum. Chem Pharm Bull. 2002;50(11):1495–8.
13. Park JY, Kim KA, Kim SL, Park PW. Quantification of gliclazide by semi micro HPLC: application to a bioequivalence study of 2 formulations in healthy subjects. J Pharm Biomed Anal. 2004;35:943–9.
14. Overhoff KA, Engstrom JD, Chen B. Novel ultra rapid freezing particle engineering process for enhancement of dissolution rates of poorly water soluble drugs. Eur J Pharm Biopharm. 2007;65:57–67.
15. Theeuwes F, Swanson DR, Guittard G, Ayer A, Khanna S. Osmotic delivery systems for the β-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol. 1985;19(2):69–76.
16. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release. 1995;35:1–21.
17. Kumar P, Singh S, Rajnikanth PS, Mishra B. An overview of osmotic pressure controlled release oral formulation. J Pharm Res. 2006;5:34–45.
18. Haslam JL, Rork GS. Controlled Porosity Osmotic Pump. U.S. Patent 4,880,631, November 14 1989.
19. Varshosaz J, Tavakoli N, Enteshary S. Enhancement of anti-diabetic effects of gliclazide using immediate release tablets in streptozotocin-induced diabetic and normal rats. Farmacia. 2013;61(4):820–36.
20. Özkan Y, Atay T, Díkman N, Isimer A, Aboul-Enein YH. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with ß-cyclodextrin. Pharm Acta Helv. 2000;74:365–70.
21. Winters S, York P, Timmins P. Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur J Pharm Sci. 1997;5:209–14.
22. Sapkal NP, Kilor VA, Bhusari KP, Daud AS. Evaluation of some methods for preparation of gliclazide- ß-cyclodextrin inclusion complexes. Trop J Pharm Res. 2007;6(4):833–40.
23. Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie. 2002;57:191–3.
24. Hong SS, Lee SH, Lee YJ, Chung SJ, Lee MH, Shim CK. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide. J Control Release. 1998;51:185–92.
25. Biswal S, Sahoo J, Murthy PN, Giradkar PR, Avari JG. Enhancement of dissolution rate of gliclazide using solid dispersions with polyethylene glycol 6000. AAPS PharmaSciTech. 2008;9(2):563–70.
26. Biswal S, Sahoo J, Murthy PN. Physicochemical properties of solid dispersions of gliclazide in polyvinylpyrrolidoneK-90. AAPS PharmSciTech. 2009;10(2):329–34.
27. Ford JL. The current status of solid dispersions. Pharm Acta Helv. 1986;61:69–88.
28. Chokshi R, Zia H. Hot-melt extrusion technique: a review. Iran J Pharm Res. 2004;3:3–16.
29. Crowley MM, Feng Z, Repka MA, Thumma S, Upadhye SB, Battu SK, et al. Pharmaceutical applications of hot-melt extrusion: part I. Drug Dev Ind Pharm. 2007;33:909–26.
30. Breitenbach J, Wiesner B. The use of polymers in pharmaceutical melt extrusion. ExAct. 2008;20:8–11.
31. Kolter K, Maschke A. Melt extrusion for pharmaceuticals. ExAct. 2009;22:2–5.
32. Shah PP, Mashru RC. Development and evaluation of artemether taste masked rapid disintegrating tablets with improved dissolution using solid dispersion technique. AAPS PharmSciTech. 2008;9(2):494–500.
33. DiNunzio JC, Brough C, Miller DA, Williams 3rd RO, McGinity JW. Applications of KinetiSol dispersing for the production of plasticizer free amorphous solid dispersions. Eur J Pharm Sci. 2010;40(3):179–87.
34. Stukalin EB, Douglas JF, Freed KF. Plasticization and antiplasticization of polymer melts diluted by low molar mass species. J Chem Phys. 2010;132(8):084504. doi:10.1063/1.3304738.
35. Mohammed NN, Majumdar S, Singh A, Deng W, Murthy NS, Pinto E, et al. Klucel™ EF and ELF polymers for immediate-release oral dosage forms prepared by melt extrusion technology. AAPS PharmSciTech. 2012;13(4):1158–69.
36. Ghosh I, Snyder J, Vippagunta R, Alvine M, Vakil R, Tong WQ, et al. Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder. Int J Pharm. 2011;419(1–2):12–9.
37. Picker-Freyer KM, Durig T. Physical mechanical and tablet formation properties of hydroxypropylcellulose: in pure form and in mixtures. AAPS PharmSciTech. 2007;8(4):E92. doi:10.1208/pt0804092.
38. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64–74.
39. Verma RK, Garg S. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur J Pharm Biopharm. 2004;57:513–25.
40. Schultz P, Kleinebudde CK. A new multiparticulate delayed release system Part I: dissolution properties and release mechanism. J Control Release. 1997;47(2):181–9.
41. Costa P, Lobo JMS. Modelling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–33.
42. Singhvi G, Shah A, Yadav N, Saha RN. Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Drug Dev Ind Pharm. 2013. doi:10.3109/03639045.2013.850706.
43. Samtani MN, Vaccaro N, Cirillo I, Matzke GR, Redman R, Nandy P. Doripenem Dosing Recommendations for Critically ill Patients Receiving Continuous Renal Replacement Therapy. ISRN Pharmacol. 2012. doi: 10.5402/2012/782656 DOI:10.5402%2 F2012%2 F782656#pmc_ext
44. Frey N, Laveille C, Paraire M, Francillard M, Holford NHG, Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol. 2002;55:147–57.
45. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47–60.
46. Sheen PC, Khetarpal VK, Cariola CM, Rowlings CE. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharm. 1995;118:221–7.
47. Hu J, Johnston KP, Williams III RO. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci. 2003;20:295–303.
48. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Control Release. 1985;1(3):269–82.
49. Appel LE, Zentner GM. Use of modified ethyl cellulose lattices for microporous coating of osmotic tablets. Pharm Res. 1991;8(5):600–4.
50. Shokri J, Ahmadi P, Rashidi P. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm. 2008;68:289–97.
51. Sakellarious P, Rowe RC. The morphology of blends of ethylcellulose with hydroxypropyl methylcellulose as used in film coating. Int J Pharm. 1995;125(2):289–96.
52. Kamba M, Seta Y, Kusai A, Ikeda M, Nishimura K. A unique dosage form to evaluate the mechanical destructive forces in the gastrointestinal tract. Int J Pharm. 2000;208(1):61–70.
53. Kamba M, Seta Y, Kusai A, Nishimura K. Evaluation of the mechanical destructive force in the stomach of dog. Int J Pharm. 2001;228(2):209–17.
54. Najib N, Idkaidek N, Beshtawi M, Bader M, Admour I, Alam SM, et al. Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide® & Diamicron®)—in healthy human volunteers. Biopharm Drug Dispos. 2002;23(5):197–202.
55. Summary of Product characteristics of Diamicron® MR 30 mg. Available from http://www.medicines.ie/medicine/1789/SPC/Diamicron. Accessed 25 April 2014.
56. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46:92–125.
57. Campbell DB, Adrianessens P, Hopkins YW, Gordon B, Williams JRB. Pharmacokinetics and metabolism of gliclazide: a review. In: Keen H, editor. Gliclazide and the treatment of diabetes. London: Academic Press and the Royal Society of Medicine; 1980. p. 71–82.
58. Frey N. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol. 2002;55:147–57.